<DOC>
	<DOCNO>NCT02505243</DOCNO>
	<brief_summary>The aim study evaluate RBV plasma concentration use combination newly develop DAA combination . If possible , correlation SVR rate incidence anaemia assess HCV-patients .</brief_summary>
	<brief_title>Evaluation RIBAvirin Plasma COncentrations Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens</brief_title>
	<detailed_description>Ribavirin ( RBV ) synthetic guanosine analogue use treat patient infect hepatitis C virus ( HCV ) . For many year , RBV cornerstone HCV treatment combination peg interferon ( PEG-IFN ) . Since development direct-acting antiviral ( DAA ) , PEG-IFN free treatment regime become first choice HCV treatment Netherlands . RBV still play important role regimen . The European Association Study liver ( EASL ) include RBV PEG-IFN free regimen combination sofosbuvir , simeprevir daclatasvir HCV genotype ( GT ) 1 , 3 4 . Patients predictor poor response candidate DAA therapy combine RBV , instance prior null responder and/or patient cirrhosis . For treatment genotype 2 ( GT2 ) 3 RBV use combination sofosbuvir . Chronic HCV infection treat combination therapy , therefore manufacturer develop combination tablet Gilead 's Harvoni ( ledipasvir + sofosbuvir ) Abbvie 's 3D combination ( paritaprevir , ombitasvir , dasabuvir ritonavir ) . Possibly , RBV add regime future patient prior null responder suffer cirrhosis . As RBV guanine analogue specific HCV severe adverse effect know . The important adverse effect haemolytic anaemia , usually occur first week treatment ( &gt; 10 % treated patient , depend co-medication ) . Other adverse reaction frequently report : neutropenia , anorexia , depression/insomnia , headache , dizziness , dyspnea , cough 5 . In dual ( PEG-IFN + RBV ) HCV therapy RBV concentration associate efficacy toxicity . Also former study HCV-infected patient treat telaprevir ( TVR ) boceprevir ( BOC ) combination PEG-IFN , plasma concentration RBV associate Sustained Virologic Response ( SVR ) anaemia ( define Hb &lt; 8,5 g/dL ) . We try determine optimal therapeutic range RBV combine DAAs . The plasma concentration RBV week 8 2.2-5.3 mg/L combination TVR . 48 % HCV patient cohort plasma concentration 81 % achieve SVR 5.2 % report anaemia . In combination BOC plasma concentration 2.2-3.6 mg/L , 50 % patient concentration . In group 69 % patient achieve SVR 46 % anaemia . So , therapy , therapeutic range RBV could define optimal SVR rate lowest incidence anaemia 6 , 7 . As TVR BOC replace novel DAAs , would like investigate describe relationship RBV concentration , SVR anaemia also newer DAAs license last year ( simeprevir sofosbuvir ) go available 2015 The Netherlands ( daclatasvir , Harvoni , Abbvie 3D combo ) . The aim study evaluate RBV plasma concentration use combination newly develop DAA combination . If possible , correlation SVR rate incidence anaemia assess HCV-patients .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>HCVinfected patient Patient must treat ribavirin . The dosage ribavirin may vary , different center different protocol RBV dose . Patient must treat one DAAs ( simeprevir , sofosbuvir , daclatasvir , ledipasvir , paritaprevir , ombitasvir , dasabuvir ) . At least 18 year age start treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>ribavirin</keyword>
	<keyword>direct-acting antiviral</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>therapeutic drug monitoring</keyword>
</DOC>